(Millions) | 2013 | 2012 | 2011 | |||||
Stock appreciation rights ("SARs") (1) | 1.7 | 8.3 | 12.4 | |||||
Market stock units ("MSUs") (2) | .4 | .2 | — | |||||
Performance stock units ("PSUs") (2) | .7 | .5 | .3 | |||||
Performance stock appreciation rights ("PSARs") (2) | .7 | — | — | |||||
(1) | SARs are excluded from the calculation of diluted EPS if the exercise price is greater than the average market price of Aetna common shares during the period (i.e., the awards are anti-dilutive). |
(2) | PSUs, certain MSUs with performance conditions, and PSARs are excluded from the calculation of diluted EPS if all necessary performance conditions have not been satisfied at the end of the reporting period (refer to Note 12 beginning on page 121 for additional information about PSARs). |